- Home
- OBIO vs GRX Comparison
OBIO vs GRX Comparison
Compare OBIO & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- GRX
- Stock Information
- Founded
- OBIO 2017
- GRX 2007
- Country
- OBIO United States
- GRX United States
- Employees
- OBIO N/A
- GRX N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- GRX Finance/Investors Services
- Sector
- OBIO Health Care
- GRX Finance
- Exchange
- OBIO Nasdaq
- GRX Nasdaq
- Market Cap
- OBIO 200.1M
- GRX 165.9M
- IPO Year
- OBIO N/A
- GRX N/A
- Fundamental
- Price
- OBIO $4.88
- GRX $9.93
- Analyst Decision
- OBIO Strong Buy
- GRX
- Analyst Count
- OBIO 4
- GRX 0
- Target Price
- OBIO $15.75
- GRX N/A
- AVG Volume (30 Days)
- OBIO 53.8K
- GRX 39.7K
- Earning Date
- OBIO 11-12-2024
- GRX 01-01-0001
- Dividend Yield
- OBIO N/A
- GRX 5.98%
- EPS Growth
- OBIO N/A
- GRX N/A
- EPS
- OBIO N/A
- GRX 0.26
- Revenue
- OBIO $2,647,000.00
- GRX N/A
- Revenue This Year
- OBIO $12.39
- GRX N/A
- Revenue Next Year
- OBIO $120.99
- GRX N/A
- P/E Ratio
- OBIO N/A
- GRX $38.50
- Revenue Growth
- OBIO N/A
- GRX N/A
- 52 Week Low
- OBIO $4.22
- GRX $7.73
- 52 Week High
- OBIO $10.46
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- OBIO 43.91
- GRX 38.86
- Support Level
- OBIO $4.78
- GRX $9.76
- Resistance Level
- OBIO $5.84
- GRX $10.46
- Average True Range (ATR)
- OBIO 0.42
- GRX 0.12
- MACD
- OBIO -0.04
- GRX -0.04
- Stochastic Oscillator
- OBIO 24.24
- GRX 30.26
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.